Cytori Therapeutics (CYTX) in Focus: Stock Rises 15%

Cytori Therapeutics, Inc. CYTX was a big mover last session with its shares rising almost 15% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost over 16% in the past one-month time frame.

This cell therapy company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate has, however, moved lower over the same period. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday's rally can last.

Cytori Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is positive.

Investors interested in the biomedical sector may, however, consider Gilead Sciences Inc. GILD which sports a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CYTORI THERAPEU CYTX: Free Stock Analysis Report
 
GILEAD SCIENCES GILD: Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research